Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Steady_T is a "soft" basher in AVXL stock
Good luck and GOD bless,
U.S. public charging sites to outnumber gas stations by 2032: Bloomberg
https://www.teslarati.com/us-public-charging-outnumber-gas-stations/
Good luck and GOD bless,
Doc328: Do you believe that the following is in general true or false???
Alzheimer's disease is easier to treat at the earliest stage possible. See the image below to understand why this is true.
The goal is to get blarcamesine to be FDA approved, then doctors can prescribe blarcamesne as a stand alone drug for many different stand alone indications including Alzheimer’s disease and/ or MCI etc.
Good luck and GOD bless,
ignatiousrielly,
I know of no pumpers on this or any other AVXL discussion board.
Exactly who have you been disparaging in comparing this someone to "kund"
Good luck and GOD bless,
EXCELLENT VIDEO!!!
VERY WELL DONE!!!
Good luck and GOD bless,
Tesla supplier announces $28 million facility near Giga Texas
https://www.teslarati.com/tesla-supplier-28-million-giga-texas/
Good luck and GOD bless,
Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study
Alan K Percy 1 , Jeffrey L Neul 2 , Timothy A Benke 3 , Elizabeth M Berry-Kravis 4 , Daniel G Glaze 5 , Eric D Marsh 6 , Amy M Barrett 7 , Di An 8 , Kathie M Bishop 8 , James M Youakim 9
Affiliations collapse
Affiliations
1 Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
2 Department of Pediatrics, Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, TN, USA.
3 Department of Pediatrics, Children's Hospital of Colorado/University of Colorado School of Medicine, Aurora, CO, USA.
4 Departments of Pediatrics, Neurological Sciences and Biochemistry, Rush University Medical Center, Chicago, IL, USA.
5 Department of Pediatrics and Neurology, Texas Children's Hospital/Baylor College of Medicine, Houston, TX, USA.
6 Division of Child Neurology, Children's Hospital of Philadelphia, Departments of Neurology and Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
7 Patient-Centered Outcomes Assessment, RTI Health Solutions, Research Triangle Park, NC, USA.
8 Acadia Pharmaceuticals, Inc., San Diego, CA, USA.
9 Acadia Pharmaceuticals, Inc., San Diego, CA, USA. Electronic address: jyouakim@acadia-pharm.com.
PMID: 39025065 DOI: 10.1016/j.medj.2024.06.007
Abstract
Background: Trofinetide was approved for the treatment of Rett syndrome (RTT) in patients aged =2 years based on the results of the 12-week, randomized, phase 3 LAVENDER study. In LILAC, a 40-week, open-label extension study of LAVENDER, trofinetide continued to improve the symptoms of RTT, with a similar safety profile as LAVENDER. Here, we report long-term safety and efficacy results of LILAC-2, a 32-month, open-label extension study.
Methods: Females aged 5-22 years who completed LILAC were eligible to enter LILAC-2. Safety and tolerability were assessed with the incidence of adverse events (AEs). Efficacy was assessed with Rett Syndrome Behaviour Questionnaire (RSBQ) and Clinical Global Impression-Improvement (CGI-I) scores. Caregiver interviews explored the patient's experience with RTT and the efficacy of trofinetide during study participation.
Findings: In total, 77 participants were enrolled in LILAC-2. The most common AEs were diarrhea (53.2%), COVID-19 (27.3%), and vomiting (19.5%). The mean (standard error [SE]) change in RSBQ score from LAVENDER baseline to week 104 of LILAC-2 was -11.8 (2.45). The mean (SE) CGI-I score from LILAC baseline to week 12 of LILAC-2 was 3.1 (0.10). Most caregivers (96%; n = 24/25) were satisfied or very satisfied with the benefits of trofinetide.
Conclusions: Long-term treatment with trofinetide continued to improve RTT symptoms, without new safety concerns. Caregivers reported satisfaction with trofinetide related to improvements that were meaningful for their child and themselves.
https://www.cell.com/med/fulltext/S2666-6340(24)00253-8?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666634024002538%3Fshowall%3Dtrue
Good luck and GOD bless,
Each of the participants in the Anavex OLE Alzheimer's study are taking the maximum tolerable dose for each participant.
Good luck and GOD bless,
Tesla primed to conquer stronger demand with Giga Shanghai output levels
"...Through the first half of the year, Tesla has delivered 830,766 cars, putting it at a pace of just over 1.6 million for 2024. This would be a decline compared to 2023 when Tesla reported 1.81 million vehicle deliveries...."
SHORT SQUEEZE on AVXL stock!!!
Good luck and GOD bless,
Part A of the phase 2 Anavex 3-71 schizophrenia trial has been completed. I believe that Part B of the phase 2 Anavex 3-71 schizophrenia trial will be completed before the end of summer 2024.
https://classic.clinicaltrials.gov/ct2/show/NCT06245213
Good luck and GOD bless,
Expect well over 5 million shares to be bought today maybe even 10 million shares bought.
Short squeeze Friday!!!
Good luck and GOD bless,
Expect well over 5 million shares of AVXL to be bought today possibly much much higher.
Good luck and GOD bless,
I believe that there will be over 5 million shares ov AVXL stock bought today with a possibly of over 10 million shares of AVXL shares bought today in anticipation of news NEXT WEEK which could trigger short covering.
Good luck and GOD bless,
These both appear to be oral presentations.
Good luck and GOD bless,
Anavex’s Innovative Alzheimer’s Therapy Blarcamesine Has Been Approved For EMA Marketing Authorization Application. What’s Next?
https://washingtonindependent.org/anavexs-innovative-alzheimers-therapy-blarcamesine-has-been-approved-for-ema-marketing-authorization-application/
Good luck and GOD bless,
Tesla stock set for ten-fold surge on Robotaxi: ARK Invest
"...Wood says the autonomous taxi ecosystem is worth between $8 trillion and $10 trillion in global revenue, and Tesla has a chance to take as much as half of the market if it can beat competitors to a fully self-driving platform...."
Explosion, fire at Irving Oil refinery
https://atlantic.ctvnews.ca/explosion-fire-at-irving-oil-refinery-in-n-b-1.4125624?cache=ihcaobeag%3FclipId%3D89680
Huge Fire Engulfs Philadelphia Refinery, the Largest on the East Coast
https://www.thedailybeast.com/philadelphia-fire-huge-blaze-engulfs-city-refinery-explosions-reported
1 Killed, 3 Hurt in Oil Well Fire
https://www.ien.com/safety/news/20782918/1-killed-3-hurt-in-north-dakota-oil-well-fire
Good luck and GOD bless,
Tesla bears officially have their next big threat: Tesla Energy
https://www.teslarati.com/tesla-tsla-bears-officially-have-their-next-big-threat-tesla-energy/
Good luck and GOD bless,
Tesla Giga Shanghai is back to operating at full capacity: report
https://www.teslarati.com/tesla-giga-shanghai-back-operating-full-capacity/
Good luck and GOD bless,
Tesla Cybertruck is ready for Full Self-Driving with v12.5, Musk confirms
https://www.teslarati.com/tesla-confirms-cybertruck-ready-full-self-driving-v12-5-elon-musk/
Good luck and GOD bless,
Abe,
I am sorry but the Phase2b/3 Alzheimer’s disease treatment trial using blarcamesine did NOT include any patients in Spain.
It included patients in and from Australia, the UK, Canada, the Netherlands and Germany.
There could however have been multiple ethnicities in each of those countries that participated in the trial.
The blarcamesine Parkinson’s disease trial originated in Spain and was expanded later during the trial to include Australian participants.
Good luck and GOD bless,
Coming presentations by Anavex
26 July 2024 three presentations concerning Anavex at the Fragile X conference
27 July 2024 one presentation regarding Anavex at the Fragile X conference
28 July 2024 one presentation concerning Anavex at the Alzheimer’s disease conference
29 July 2024 one presentation concerning Anavex at the Alzheimer’s disease conference
6 presentations in total
Good luck and GOD bless,
There will be 4 presentations by Anavex’s chief scientific officer next week at the Fragile X syndrome conference. The week after starting 28 July there will be 2 additional presentations concerning Anavex at AAIC Alzheimer’s disease conference.
Good luck and GOD bless,
Over 5 million shares will be bought tomorrow with the possibility of over 10 million shares bought in anticipation of the GREAT NEWS within the next two weeks regarding AVXL from the Fragile X syndrome conference and the AAIC Alzheimer’s disease conference.
SHORT SQUEEZE coming SOON!!!
Good luck and GOD bless,
SHORT SQUEEZE on AVXL stock, SOON!!!
Good luck and GOD bless,
Expect AVXL stock to close at or near the high of the day on large volume at the close.
Good luck and GOD bless,
In anticipation of GREAT NEWS NEXT WEEK and the FOLLOWING WEEK expect HUGE buying volume in AVXL stock this Friday! 19 July 2024!!!
Good luck and GOD bless,
SAVA has had a lot of shares traded today so far.
AVXL stock seems to be down in sympathy for SAVA.
BUT we have a lot of good news concerning AVXL to be released during the next few weeks, very soon!!!
Good luck and GOD bless.
You are absolutely correct about the following:
something stinks in Denmark 🦨💩
Dr. Daniel Klamer PhD is still listed on slide/page #32 on the July 2024 Corporate Presentation.
https://www.anavex.com/_files/ugd/79bcf7_34621a802cb94006ba8b91012327d541.pdf
IT appears that the main purpose of lide/page #32 on the July 2024 Corporate Presentation was to introduce several new senior employees to the stockholders.
They have almost 50 employees if not more by now. There is not typical to list all employees on every Corporate Presentation.
QUIT MAKING UP NONSENSE!!!
GOD bless,
There are currently at least 2 former FDA employees working at Anavex Life Sciences.
GOD bless,
AVXL $5.83
Volume: 1,687,642
Good luck and GOD bless,
Institutional funds have a still are buying and accumulating AVXL stock!!!
Good luck and GOD bless,
I believe that the paper for the Phase 2b/3 trial for Alzheimer's disease treatment using blarcamesine will be published this week or nest week in a peer reviewed journal.
Good luck and GOD bless,
Anavex will be attending and presenting at the following conference in less than 2 weeks.
Alzheimer's Association International Conference®
July 28 – Aug. 1, 2024
https://aaic.alz.org
Good luck and GOD bless,
ABSOLUTE NONSENSE!!!
The following is a FACT!!!
Dr. Kaufmann is highly respected and is making these presentations regarding Fragile X syndrome and Rett syndrome, because he is the best person at Anavex Life Sciences to make these presentations.
Good luck and GOD bless,
Expect AVXL to close at or near the high of the day with over 1.5 million and possibly over 2 million shares bought before the close of trading in anticipation of news.
Good luck and GOD bless,
Coming on Saturday 27 July 2024
Relationship between cognitive and behavioral impairment in children in fragile X syndrome: a latent class analysis of FORWARD data
Fragile X Syndrome (FXS)Research
3:00 PM – 4:30 PM
Oceans 9
IN-PERSON
RECORDED
Description
In a previous analysis of FORWARD data, using latent class analysis (LCA), we identified clinically meaningful behavioral subtypes in children in FXS. To better understand the relationship between cognitive and behavioral impairment in FXS, we conducted a follow-up study of the same dataset incorporating cognitive data to the LCA. We found 5 groups representing the spectrum of Intellectual disability (ID), from predominantly no ID or developmental delay (DD) to mainly moderate to severe ID. While the proportion of individuals with Irritability/Agitation, Aggression, and Self-injury (IAAS) was directly correlated with the level of ID, other behavioral conditions (e.g., attention problems, autistic behavior), were less closely associated with ID level.
Speaker
Walter Kaufmann, Anavex Life Sciences Corp./Dept. Human Genetics, Emory Univ. School of Medicine, Chief Scientific Officer, Adjunct Professor
Good luck and GOD bless,